Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Opus Genetics ( (IRD) ).
On February 13, 2026, Opus Genetics, Inc. entered into a securities purchase agreement with certain investors for a private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock, which closed on February 18, 2026, raising approximately $25.0 million at $3.39 per share. The proceeds are earmarked to advance the company’s gene therapy clinical programs and general purposes, with the preferred shares set to automatically convert into common stock on a one-for-one basis following stockholder approval of an increase in authorized common shares, subject to ownership limits.
In connection with the financing, Opus executed a registration rights agreement on February 18, 2026, committing to register the resale of common shares issuable upon conversion of the Series B Preferred Stock, with a filing deadline for the initial registration statement set no later than April 19, 2026. The company also filed a Certificate of Designation in Delaware to establish the rights of the Series B Preferred Stock, which carries as-converted dividend rights, limited protective voting rights, parity with common stock in liquidation, and conversion caps designed to prevent any holder from exceeding a specified beneficial ownership threshold.
The most recent analyst rating on (IRD) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
Spark’s Take on IRD Stock
According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.
The score is held down primarily by weak financial performance (large losses and significant cash burn), partially offset by constructive technical trend signals and positive corporate developments (pipeline/regulatory progress and improved cash runway). Valuation is constrained by negative earnings and no provided dividend support.
To see Spark’s full report on IRD stock, click here.
More about Opus Genetics
Opus Genetics, Inc. operates in the biotechnology sector, focusing on developing gene therapy clinical programs. The company is oriented toward advancing treatments that leverage genetic technologies, positioning it within the broader market for innovative therapeutic solutions and relying on external financing to support its research and corporate operations.
Average Trading Volume: 716,110
Technical Sentiment Signal: Hold
Current Market Cap: $268.3M
For a thorough assessment of IRD stock, go to TipRanks’ Stock Analysis page.